What is behind Eye Health & Vision
Age-related macular degeneration — loss of cells in the macula, the part of the retina that carries straight-ahead vision. Evidence A — Human trial evidence.
Macular pigment optical density — the lutein and zeaxanthin your retina concentrates into the macula. Evidence A — Human trial evidence.
Glaucoma — progressive loss of retinal ganglion cells and optic nerve fibers. Damage often goes undetected until sight is permanently gone. Evidence B — Preclinical.
Cataract — clouding of the lens, the leading cause of blindness worldwide. Sorbitol accumulation, glycation and oxidative damage aggregate the crystallin proteins that keep the lens clear. Evidence B — Preclinical.
Dry eye — ocular surface disease, the most common ophthalmic complaint. Evidence B — Preclinical.
Myopia — short-sightedness driven by excessive axial elongation of the eyeball. Uncorrected refractive error is the single largest cause of vision impairment worldwide. Evidence B — Preclinical.
Diabetic retinopathy — damage to retinal blood vessels causing them to leak or bleed. The leading cause of new blindness in working-age adults. Evidence A — Human trial evidence.
The ciliary muscle holds its contraction for as long as you hold your attention on something near. Distance is the resting state; everything closer is work you never decided to begin. Evidence A — Human trial evidence.
The ache, the blur and the reluctance that arrive after a stretch of near work. It is the measurable consequence of accommodation held too long, and it is scored on validated strain instruments rather than asked about. Evidence A — Human trial evidence.
The hungriest cells you own. They tear down and rebuild their own working surface every single day, because catching light consumes them that fast, and they do not come back.
The retina depends on its pigment density (lutein and zeaxanthin), blood flow and antioxidant defense. Supporting these shields the macula from age-related and light stress. Evidence B — Preclinical.
Evidence on these pathways
Accommodation (focusing effort) → Eye Fatigue & Strain. “When near demand approaches or exceeds this reserve capacity, visual fatigue and symptoms emerge.” — Accommodative Insufficiency. StatPearls, 2026. PMID 36508537
Oxidative Stress (ROS) → Photoreceptor Survival. Reactive oxygen species kill the cells that read light: radicals rose in 661W photoreceptor cells and in primary retinal cells but not in RGC-5 ganglion cells, with outer-nuclear-layer thinning and TUNEL-positive cells increasing, and the free-radical scavenger edaravone prevented both. — J Pharmacol Sci 2012;118(3):351-62. doi:10.1254/jphs.11110FP
Omega-3 / EPA-DHA → Dry Eye / Ocular Surface. “While after 8wk TBUT (6.00±1.62s vs 5.08±1.28s, P=0.034) and MGD score (7.2±1.8 vs 8.1±2.6, P=0.033) in the omega-3 group was more significantly improved than that of the placebo group.” — Effects of dietary high dose DHA omega-3 supplement in dry eye with meibomian gland dysfunction. International Journal of Ophthalmology 2021;14(11):1700-1706. doi:10.18240/ijo.2021.11.08
Formulas that act on these pathways
Acts on 10 of these pathways: Macular Degeneration (AMD), Macular Pigment Density, Glaucoma (Optic Neuropathy), Cataract (Lens Opacity), Dry Eye / Ocular Surface, Myopia / Axial Elongation, Diabetic Retinopathy, Accommodation (focusing effort), Eye Fatigue & Strain, Photoreceptor Survival.
What this page does not claim
This page names the pathways involved and the published evidence on each. It does not claim that any formula treats, cures or prevents Eye Health & Vision. A pathway opens here only on graded, published evidence, under a standard fixed before the evidence was gathered, and every figure above carries its grade.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.